When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care.

Personal genome analysis available online

Dr Jenna Lester talks about disparities in dermatologic care and its contributions to health inequities during this COVID-19 pandemic and beyond. 

Dr Nancy Krieger talks about the importance of good science to inform public policy that address longstanding health inequities during this COVID-19 pandemic and beyond.

There is a market for direct-to-consumer genetic testing and a need for better consumer information and more regulation of tests and testing laboratories.

Research questions must be answered to inform policy decisions about the hereditary diseases and conditions for which newborns should be tested.

The question of whether and how results from personal genetic testing will motivate behavioral changes in consumers has only begun to receive the research attention it richly deserves.

Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients.

The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient.

Physicians should provide women considering abortion after Down syndrome screening with unbiased information and not attempt to influence their decision.